OS
Oxford Sciences Innovation
Oxford, United KingdomFounded 2015
Biotech & Life SciencesHardware & SemiconductorsHealthcareConsumerCybersecurityDeveloper ToolsRobotics & Automation
Oxford Sciences Innovation (now Oxford Science Enterprises) is a venture capital firm that invests in and supports spin-out companies from the University of Oxford, aiming to commercialize the university's groundbreaking research and technology. Their strategy involves providing funding, expertise, and resources to these startups across all development stages, with a focus on areas like life sciences, healthcare, deep tech, AI, and digital health.
30% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (40% of deals). Average disclosed round size is $32.8M (across 10 rounds with reported amounts).
Portfolio
10
Fund Size
$1.6B
Top Stage
Series A
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Ultromics | Series B | $33M | Aug 2021 |
 PepGen, Inc. | Growth | $112.5M | Aug 2021 |
 Rey | Series A | $10M | Jul 2021 |
 Evox Therapeutics | Series C | $95.4M | Feb 2021 |
 PQShield | Seed | $7M | Jul 2020 |
 Quantum Motion | Series A | $9M | May 2020 |
| BBodle Technologies | Series A | $6M | Jan 2018 |
| DDiffblue | Series A | $22M | Jun 2017 |
| SSpyBiotech | Seed | $5M | Mar 2017 |
| AAnimal Dynamics | Unknown | $27.6M | — |
Top Co-Investors
GV (Google Ventures)3 shared
Optum Ventures2 shared
Kindred Ventures2 shared
Parkwalk Advisors2 shared
Redmile Group1 shared
OrbiMed1 shared
Invus1 shared
Cowen Healthcare Investments1 shared
Eli Lilly1 shared
Octopus Ventures1 shared
INKEF Capital1 shared
IP Group1 shared
Crane1 shared
Deutsche Bank1 shared
Blue Venture Fund1 shared
RA Capital Management1 shared
Last updated: 16 April 2026